All In Biotech

Investigational drug · Phase 3

NSC 613327

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer, Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

13

Any phase or sponsor naming "NSC 613327"

First trial start

2023

Apr 12, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NSC 613327", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Locally Advanced Triple-negative Breast Cancer
  • Metastatic Triple-negative Breast Cancer
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Advanced Triple-Negative Breast Cancer

Approved drugs for the same conditions: Breast cancer · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "NSC 613327" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Locally Advanced Triple-negative Breast Cancer

  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • BEBT-209KCBI-0191Phase 33 trials

    BeBetter Med Inc · HR+/HER2- Locally Advanced, Metastatic Breast Cancer, Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.